News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines Second-generation vaccines that combine different advanced DNA, RNA, Protein, and Adjuvant components are critical to providing accessible, broad, and durable protection against current and future likely SARS-CoV-2 variants By adding self-amplifying self-adjuvating RNA (SASA-RNA), next-generation nano-lipid carriers, recombinant protein, and adjuvant vaccine technologies to ImmunityBio’s current adenovirus vector vaccine, the company offers one of the most comprehensive vaccine technology platforms Such combination approaches are already being studied in trials in South Africa, including the fully enrolled Phase 2 SISONKE Boost trial, which is studying ImmunityBio’s hAd 5 as a boost to the Janssen COVID-19 prime This vaccine consortium is designed to create a comprehensive technology platform to serve as a foundation for the large-scale manufacture of multiple vaccine vectors for pandemic preparedness and for the treatment of cancer https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-expands-vaccine-program-accelerate-use-mix-and-match?field_nir_news_date_value[min]=

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. grew its stake in ImmunityBio by 48.4% in the 2nd quarter. BlackRock Inc. now owns 5,273,157 shares of the company’s stock worth $75,300,000 after acquiring an additional 1,719,492 shares during the period. Glenmede Trust Co. NA purchased a new stake in ImmunityBio in the 1st quarter worth approximately $1,809,000. Goldman Sachs Group Inc. purchased a new stake in ImmunityBio in the 1st quarter worth approximately $1,926,000. Rhumbline Advisers grew its stake in ImmunityBio by 135.3% in the 2nd quarter. Rhumbline Advisers now owns 89,140 shares of the company’s stock worth $1,273,000 after acquiring an additional 51,249 shares during the period. Finally, Illinois Municipal Retirement Fund purchased a new stake in ImmunityBio in the 2nd quarter worth approximately $228,000. Hedge funds and other institutional investors own 50.38% of the company’s stock. Quelle: https://zolmax.com/investing/immunitybio-nasdaqibrx-raised-to-hold-at-zacks-investment-research/6508747.html

Sec Form 10Q veröffentlicht: "For the nine months ended September 30, 2021, we received net proceeds totaling $136.9 million from the issuance of 10,216,978 shares under the ATM, … As of September 30, 2021, we had $359.0 million available for future stock issuances under the ATM." Keine Rede vom BLA. https://quantisnow.com/insight/2003377?s=s

Amyris, ImmunityBio Join Forces For Next-Gen COVID-19 RNA Vaccine Amyris Inc (NASDAQ: AMRS) has entered into a 50:50 joint venture arrangement with ImmunityBio Inc (NASDAQ: IBRX) to commercialize a next-gen COVID-19 vaccine. The parties have signed a binding term sheet, and a definitive agreement is in process and is expected to be executed within the next month. ImmunityBio will be responsible for manufacturing the vaccine once human trials are completed in South Africa.  Amyris will contribute its RNA technology licensed from the Infectious Disease Research Institute (IDRI).  Amyris will also provide sustainable squalene, an organic compound used to produce the vaccine. Upon completion of human trials, the joint venture's goal is to deliver one billion doses of the new vaccine in 2022. https://m.benzinga.com/article/23955257

ImmunityBio to Present at the Jefferies London Healthcare Conference CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 4, 2021-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that Founder, Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong, M.D., will deliver a company presentation at the 2021 Jefferies London Healthcare Conference, which is being held November 16-18, 2021. Dr. Soon-Shiong will present updates on ImmunityBio’s infectious disease and oncology programs. Management will be available during the conference for virtual one-on-one meetings. Presentation Details: Date: November 18, 2021

ImmunityBio, Inc. @ImmunityBio 4 hours ago: “… overall percentage of all patients with cancer who will respond to immune checkpoint inhibitors alone is less than 13%.” This underscores the importance of studies like our LungMAP trial that are looking at ways to bolster checkpoint effectiveness: https://www.science.org/doi/10.1126/scisignal.abc4764

ImmunityBio, Inc. @ImmunityBio 25. Okt. Hoag Hospital (Newport Beach, CA) is part of Nant Cancer Vaccine trial for TNBC, a disease more than 40K women will be diagnosed with this year. Learn more about our research into treatments for TNBC & other types of cancer. https://lat.ms/3b6Ll0M

Billionaire Soon-Shiong on L.A. Times, Vaccine Development https://www.bloomberg.com/news/videos/2021-10-22/billionaire-soon-shiong-on-l-a-times-vaccine-development

ImmunityBio, Inc. @ImmunityBio 17 hours ago Similar to our Nant Cancer Vaccine (https://bit.ly/3b1SCPO), this study conducted by researchers at MIT, the NCI, et al., uses low-dose chemo to cause immunogenic cell death: https://bit.ly/3ni8lzD

ImmunityBio, Inc. @ImmunityBio 22. Okt. The mix-and-match approach to COVID boosters is gaining momentum. We’re currently testing a heterologous prime-boost (hAd5 S+N) in South Africa with the goal of raising T cells and broader antibody response. Learn more: https://nyti.ms/3G9wYr3

ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease Primary endpoints were met for both Cohorts A and B of Carcinoma in Situ (CIS) and Papillary disease in the 154-patient Phase 2/3 trial studying Anktiva (N-803) and BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) In papillary disease, 57% of patients remain disease free at 12-months and with CIS disease complete response rate is 72% There were zero immune- or treatment-related severe adverse events noted in the combined safety analysis of 154 patients in the trial Key patent allowed covering Anktiva intravesical use in bladder cancer with the term extending to 2035 https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-primary-endpoint-met-second-indication?field_nir_news_date_value[min]=

ImmunityBio, Inc. @ImmunityBio vor 9 Std. Pancreatic cancer has one of the highest mortality rates, claiming almost 50,000 lives/year in the U.S. For late-stage pancreatic cancer patients, survival is measured in months—yet there have been no significant therapies in its treatment for decades.

ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date More than 50 participants in third-line cohort of QUILT 88 trial have received the Nant Cancer Vaccine, which includes ImmunityBio’s off-the-shelf, targeted natural killer cells (PD-L1 t-haNK), IL-15 receptor agonist Anktiva (N-803), and Aldoxorubicin, plus low-dose chemotherapy. Of the evaluable patients in the study’s third cohort (third-line or greater disease state), 90% (43/48) have exceeded the historical survival rates of approximately two months with standard-of-care chemotherapy. Of the 48 evaluable patients, approximately half had extremely advanced disease upon enrollment (i.e. had progressed after three to six prior lines of therapy) and, of these patients, 87% (20/23) have exceeded historical survival rates. Mature data is expected in Q1 2022 and the company plans to meet with the FDA in 2022 to discuss the path for the approval of combination therapies for pancreatic cancer. https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-completes-enrollment-phase-2-study-nant-cancer?field_nir_news_date_value[min]=

https://www.google.com/amp/s/seekingalpha.com/amp/article/4459431-immunitybio-demoralization-of-the-bulls-by-deflating-the-share-price

Any indication could make Anktiva a blockbuster product with years of patent protection and exclusivity. If Anktiva is able to pull in a $1B in revenue, we would use the industry’s average price-to-sales of 5X, which would give us a $5B valuation. Considering the company’s current market cap is around $3B-$3.5B, I would say my viewpoint is supported. In fact, I believe the company only needs Anktiva to be approved and only a few indications and claim a small percentage of the market to justify its current market cap. So, any other product candidate could be seen as gravy. My Plan In my previous IBRX article, I discussed how I had started to rebuild my IBRX position by using numerous micro-sized additions over the remainder of 2021 in anticipation of a BLA submission. Although I am extremely bullish on IBRX, the overall market environment and the bearish trend have encouraged me to continue with this strategy until we see where the ATM level is at and/or the sector catches a nice bid. Once the coast is clear, I will return to my previous strategy of “buying on dips and selling on rips” until I see IBRX establish a new "post-merger” pulse or we see a PDUFA date scheduled. Overall, my bullish conviction is at an all-time high for IBRX, and still plan to hold a long-term core position in expectation ImmunityBio will yield numerous best-in-class treatments in a variety of indications.